Durvalumab with chemo before surgery for bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with bile duct or gallbladder cancer that can be treated with surgery
- Your tumor is considered high-risk (e.g., larger than 5 cm, multiple tumors, or involves nearby lymph nodes) but has not spread to other parts of the body
- You are between 18 and 75 years old
- You are in generally good health (ECOG performance status 0 or 1)
- Your blood counts and liver/kidney function are within certain ranges
- You have not had immunotherapy or certain other cancer treatments before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine and cisplatin) before surgery helps people with a high-risk type of bile duct cancer live longer. If you qualify, you would receive the drug combination before your planned surgery.
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
This trial tests a combination of a drug (durvalumab) that helps your immune system fight cancer, plus a special heat treatment applied inside the bile duct. It is for people with bile duct cancer that cannot be removed by surgery and who need a stent to open the bile duct.
This trial tests a combination of two drugs, pemigatinib and durvalumab, for people whose advanced bile duct or gallbladder cancer has already been treated once. It aims to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of two drugs—durvalumab (an immunotherapy) and olaparib (a targeted therapy)—for people with advanced bile duct cancer that did not grow after initial treatment with chemotherapy and durvalumab. The goal is to see if this combination can help control the cancer further.
Hear when a new Resectable Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.